MPM Bioimpact LLC Sells 184,917 Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST)

MPM Bioimpact LLC trimmed its holdings in Aquestive Therapeutics, Inc. (NASDAQ:AQST - Free Report) by 10.3% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,611,833 shares of the company's stock after selling 184,917 shares during the quarter. MPM Bioimpact LLC owned approximately 1.77% of Aquestive Therapeutics worth $5,738,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. New York State Common Retirement Fund boosted its stake in Aquestive Therapeutics by 713.3% in the 4th quarter. New York State Common Retirement Fund now owns 12,200 shares of the company's stock worth $43,000 after purchasing an additional 10,700 shares during the period. Dynamic Technology Lab Private Ltd bought a new position in Aquestive Therapeutics in the 4th quarter worth approximately $44,000. PKS Advisory Services LLC bought a new position in Aquestive Therapeutics in the 4th quarter worth approximately $63,000. China Universal Asset Management Co. Ltd. bought a new position in Aquestive Therapeutics in the 4th quarter worth approximately $69,000. Finally, Price T Rowe Associates Inc. MD boosted its stake in Aquestive Therapeutics by 16.0% in the 4th quarter. Price T Rowe Associates Inc. MD now owns 27,669 shares of the company's stock worth $99,000 after purchasing an additional 3,821 shares during the period. 32.45% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have weighed in on AQST. HC Wainwright restated a "buy" rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research note on Thursday. Alliance Global Partners reaffirmed a "buy" rating on shares of Aquestive Therapeutics in a report on Friday, March 7th. Lake Street Capital decreased their price objective on Aquestive Therapeutics from $10.00 to $8.00 and set a "buy" rating on the stock in a report on Friday, March 7th. Finally, Raymond James set a $7.00 price objective on shares of Aquestive Therapeutics in a research note on Friday, March 7th. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and an average price target of $10.67.

Aquestive Therapeutics Stock Performance

Shares of NASDAQ:AQST traded up $0.02 on Monday, reaching $2.40. The company's stock had a trading volume of 1,073,391 shares, compared to its average volume of 1,507,311. The company has a market cap of $237.89 million, a P/E ratio of -5.34 and a beta of 2.02. The company has a 50-day simple moving average of $2.76 and a 200 day simple moving average of $3.34. Aquestive Therapeutics, Inc. has a 52-week low of $2.12 and a 52-week high of $5.80.

Aquestive Therapeutics (NASDAQ:AQST - Get Free Report) last issued its quarterly earnings results on Monday, May 12th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.17) by ($0.07). The company had revenue of $8.72 million during the quarter, compared to the consensus estimate of $12.23 million. On average, equities research analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Aquestive Therapeutics Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.